Atea’s polymerase inhibitor fails in late-stage Covid-19 treatment trial

Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment.

The Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA – Psychedelic Alpha

On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a two-day virtual meeting, Advancing Psychedelic Clinical Study Design. The below

February 16, 2024

The latest updates on cancer research from the weekend

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi, it’s Meghana. Lots

April 8, 2024

Netherlands sees unexpected surge in Mycoplasma pneumoniae cases, younger population more affected

A study in the Netherlands reports a significant rise in Mycoplasma pneumoniae infections since October 2023, with a notable decrease in the median age of

January 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.